Pepti Review: $99 Semaglutide, and a Number We Could Not Settle

Pepti is the cheapest compounded semaglutide program we have read a price for: $99 a month, printed on the product page, flat at every titration dose, cancellable whenever you like. It publishes that figure without asking you anything first, which is the behavior this publication exists to reward. And in the same production data that draws the page, it carries a completely different price ladder — one that runs from $299 to $449 for the same drug — which nothing on the site renders and which we could not prove is dead.

We are going to report both, because we could not settle which one you would actually be charged, and a review that quietly picks the flattering number is worse than no review.

What the page says

Injectable semaglutide is $99 a month and injectable tirzepatide is $199 a month. Both are described as one all-in price at every dose, so titrating from 0.25 mg up to a maintenance dose does not move the figure. Either can be bought once instead of subscribed to, at exactly 1.25 times the monthly price — $124 and $249 — and the multiplier holds across the catalog, which is the sort of internal consistency that suggests a real pricing engine rather than hand-typed marketing.

Subscriptions cancel at the end of the cycle with no minimum term, and can be paused for up to 90 days. There is no membership fee sitting on top.

The rest of the shelf is deep. Oral semaglutide is $249 and oral tirzepatide $399; GLP-1 oral drops are $239 and a GLP-1/GIP drop is $349; there are two explicitly labeled longevity microdose products at $149 and $229. Beyond the GLP-1 line there are recovery and longevity peptides — BPC-157 at $209, a BPC-157/TB-500 stack at $289, KPV at $229, sermorelin and tesamorelin at $189 each, CJC-1295 with ipamorelin at $239, NAD+ in three routes from $159 to $219, DSIP for sleep at $189 — plus at-home hormone and metabolic blood panels at $199, or $169 with a plan.

The ladder that renders nowhere

Here is the finding we cannot resolve.

The server payload for the semaglutide and tirzepatide pages carries an array of per-dose options with their own prices: semaglutide at $299 for 0.25 mg, $349 for 0.5 mg, $399 for 1.0 mg and $449 for 2.4 mg; tirzepatide at $349, $399, $449 and $549 across its dose steps. No component on the site reads that array. It appears in the data that builds the page and then goes nowhere — nothing renders it, nothing prices from it, and a reader would never see it.

Meanwhile the cost page states, in the site's own words, that there is one flat monthly price at every titration dose, and repeats $99. Three other surfaces repeat it too.

So which is real? We do not know, and we want to be precise about why. We trusted the rendered figure — $99 is what the page shows, what the catalog object carries, and what four independent surfaces say — and that is what we have filed. But a per-dose ladder averaging roughly three times the headline, sitting live in production data, is not nothing. The checkout endpoint accepts only POST requests, so we could not query it for a price without submitting an order, and we do not submit orders. The contradiction is unresolved. If you are considering Pepti, the single most useful thing you can do is walk the intake to the payment screen and read the total before you confirm it — and if the number there is not $99, that is worth knowing and worth telling us.

The reason we labor this is that a strikingly cheap figure is, in our experience of reading these sites, more often a capture error than a bargain — a promotional month, a prepay total divided out, or a microdose tier read as a standard one. That is the working assumption behind every row on our prescription GLP-1 review index. Here the low number may well be right. But a second number sitting three times above it means the low one is not yet verified, and we will not print it as though it were.

Where it ships, and the answer is not fifty

Four separate surfaces — the shipping page, the state-availability page, the providers page and the homepage title itself — say Pepti operates in 36 states, and they publish the list. The terms of service say 50. Four corroborating surfaces beat one outlier sentence in a legal document, so 36 is what we treat as operative, and the states are: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Virginia and Washington. At-home blood testing ships to all fifty.

When your card is charged

The how-it-works page says you pay nothing until a physician approves your treatment. The refund policy says payment is collected at checkout, before the licensed provider reviews your intake. Those cannot both be true, and the refund policy is the operative document — it is the one that governs if anything goes wrong.

So assume you are charged before anyone has read your file. If a provider declines you, the policy promises a full refund in five to ten business days. Once medication has shipped there is no refund, which is standard for compounded prescriptions rather than particular to this seller.

Who prescribes, and who compounds

Pepti names two prescribers with full biographies: Dr. Gene Lee, MD, its medical director, board-certified in family medicine and licensed in 26 named states; and Dr. Laeeq Butt, MD MBA, its chief medical officer, an internist licensed in 15 named states. That is more than most of this cohort publishes.

What it does not publish is an NPI for either of them, which means neither biography can be checked against the national provider registry.² A named clinician with no NPI is not an accusation — plenty of real doctors are described online without one — but it is the difference between a claim and a verifiable claim, and this publication is in the business of that difference.

The pharmacy is never named. The site describes "independent FDA-registered 503A or 503B compounding pharmacies", which is a category, not a counterparty. For a compounded drug, the pharmacy is the most consequential fact about what ends up in the vial, and it is the one thing here you cannot check. The legal entity is pepti LLC at a Newark, Delaware registered-agent address rather than an operating site.

The part of the catalog we will not point you at

Pepti's shelf includes retatrutide, melanotan II and IGF-1 LR3. We are naming them so that you know they are there, and then declining to discuss them as options. Retatrutide has no FDA approval in any form, in any jurisdiction; the other two are not approvable products for the uses they are sold for. A catalog that runs an investigational shelf beside a prescription one is a fact about the company, and you should factor it in — but nothing on this site will recommend those compounds, at Pepti or anywhere else.

The warning-letter screen

We queried the FDA's live warning-letter index for the company, for its legal entity and for the surrounding peptide-seller neighborhood. Pepti did not match in the company column.³ The neighborhood is instructive, though: several wholesale peptide sellers with similar names do carry letters, which is exactly why the match has to be made on the company column rather than on a hit count. And the pass carried a positive control — a company we knew had a real 2026 letter, which returned correctly — because a screen without one cannot distinguish a clean record from a broken query.

The gut reading

Compounded semaglutide is the same molecule studied in the trials that made this class famous, where once-weekly dosing produced roughly 15% mean body-weight loss over 68 weeks.⁴ What the trials also show is that gastrointestinal events are the commonest adverse effects and a real driver of people stopping.⁵ At $99 a month the cost of finding out whether you tolerate it is unusually low, which cuts both ways: it is a lower barrier to trying, and a lower barrier to starting something you have not thought through. If nausea, reflux or constipation are what you expect to struggle with, what happens to your gut on a GLP-1 is the more useful read.

Where it lands

Pepti publishes its prices to a stranger, which is the entry condition here, and its headline number is the lowest we have verified being displayed. It names its doctors. It publishes a real state list. Against that: no named pharmacy, no NPIs, a charging policy that contradicts itself across two pages, and a live per-dose ladder in its own data that says something very different from its headline.

We file $99 and $199, we flag the contradiction, and we tell you to read the checkout total before you confirm it. For contrast, The Edit charges twice as much and had no contradiction we could find; Auren Rx sits between them with an explicit no-commitment rung on every product. None of the three pays us anything, and there is no link in this article that earns us money — this is the research library doing what it does. The programs this site does link out to, which are a different set entirely, are ranked on whether they publish a semaglutide figure before the intake in our compounded semaglutide ranking.